Friday, 21 Sep 2018

PsA/SpA

Date Typesort ascending Title Save
16 Oct 2017 Social Looking at 2 different datasets, having PsA confers a 30+% risk of Cardiovascular dz https://t.co/0OcGOUDg9T
29 Jun 2018 Social European Commission has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of adults with active psoriatic arthritis (PsA) with an inadequate response to DMARDs https://t.co/G6YYXSuUyQ
27 Jun 2016 Social RAPID3 gives similar outcome info to BASDAI and ASDAS in a cross sectional study of 85 AS patients https://t.co/uIfXJpB5s3
24 Feb 2017 Social Study of >43K Pso, PsA, AS pts shows 14-34% increase risk for depression; but not for suicide or suicidal ideation. https://t.co/STsQikW5pN
05 Nov 2017 Social RT @japaoli19: Low dose CT detects more spinal progression vs xray in AS measured by ct syndesmophyte sc #582 #ACR17 @rheumnow https://t.…
18 Jun 2015 Social Arthritis mutilans review & defined:digital telescoping/shortening, flail jts, xray resorption, pencil-in-cup change http://t.co/PXq9iPBQyZ
02 Oct 2015 Social Looking at 2 different datasets, having PsA confers a 30+% risk of Cardiovascular dz http://t.co/akU4NR3Etg
22 Mar 2018 Social FDA Approves Ilumya (tildrakizumab for Moderate-to-Severe Plaque Psoriasis. It binds p19 subunit of IL-23, inhibiting binding to IL-23 receptor. Given as 100 mg sc at Wk 0, 4 & q 12wks; 2nd IL-23 inhib approved for Pso. https://t.co/q9bQTVqN0t
09 Sep 2018 Social Excellent open review of obesity's influence on disease onset (RA, PsA), pathogenesis, disease progression, functional consequences and treatment interference. https://t.co/xaOkBrWDR4
18 Apr 2017 Social Corrona study 1,567 PsA shows patients w/ dactylitis or enthesitis had more Dz activity, Pain, Fatigue, low work,HAQ https://t.co/2UcTOZKhYf
06 Nov 2017 Social Plenary abst#1787 Landawe presents Atlas 5 study, continuation of ADA is assoc w/ signif less flares in nr-AxSpApts… https://t.co/O1xSQ6nafD
20 Jan 2017 Social Small prospective study shows a potential benefit of Vedolizumab in IBD-associated SpA. 46% pts improved @drpetryna https://t.co/pgoKO8ZabS
25 May 2017 Social Tight control (TC) trial in PsA (TiCOPA) shows that TC is twice costly & QALYs- not cost-effective in most analyses https://t.co/MxFR1wjl8N
07 Nov 2017 Social RT @DrPetryna: FUTURE5: Cosentyx clinically&radiofraph superior toPBO. mTSS non-progression 88%Cosentyx vs73% PBO #L17 #acr17 @RheumNow htt…
17 Feb 2017 Social RT @DrRachelTate: RAPID3 as a potential useful tool for PsA. Arthur Kavanaugh, MD and Eric Ruderman, MD #rwcs2017 @RWCSmtg @RheumNow https:…
09 Nov 2017 Social RT @japaoli19: @RheumNow Agree. Only 6% were strong recommendations. Glad they addressed comorbidities but management not necessarily consi…
13 Jun 2018 Social Lindstrom studied their Swedish AS registry and found that While the presence of Uveitis was assoc w/ better TNFi responses; all other comorbidities yielded lesser TNFi responses. #EULAR2018 @RheumNow OP0023 https://t.co/bltRC4khbL
30 Jul 2015 Social PSOLAR registry Infection risk w/ age, DM, smoking, prior Infx, INFLX, ADA. Low rate w/ Stelara 0.83 & ETN 1.47/100PY http://t.co/OxTbxe2HN9
03 Aug 2017 Social FDA Arthritis Advisory Panel votes 10-1 in favor of approving tofacitinib (Xeljanz) for use in Psoriatic athritis. FDA decision pending.
08 Nov 2017 Social RT @uptoTate: Increased risk of CVA, but not for MI, in AS pts. #ACR17 @RheumNow #2972 https://t.co/5opG0IudgP https://t.co/8PMXbJY7fq